-
21.发明授权公开(公告)号：US08846945B2
公开(公告)日：2014-09-30
申请号：US13462115
申请日：2012-05-02
IPC分类号： C07D257/04
CPC分类号： A61K31/41 , A61K31/4439 , A61K31/497 , A61K31/5377 , C07D241/12 , C07D257/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D407/10 , C07D409/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D491/10 , C07D491/107 , C07D498/08
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R 1为任选取代的四唑基，R 2为任选取代的苯基，任选取代的吡啶基或任选取代的噻吩基，R 3，R 4，R 5和R 6如本文所定义。 还提供了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。
-
22.发明授权公开(公告)号：US08841336B2
公开(公告)日：2014-09-23
申请号：US13240249
申请日：2011-09-22
IPC分类号： A61K31/41 , C07D213/12 , C07D471/04 , C07D401/10 , C07D405/12 , C07D257/04 , C07D409/14 , C07D401/14
CPC分类号： C07D257/04 , C07D401/10 , C07D401/14 , C07D405/12 , C07D409/14 , C07D413/12 , C07D471/04
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5, R6 R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R 1为任选取代的四唑基，R 2为任选取代的苯基，任选取代的吡啶基或任选取代的噻吩基，R 3，R 4，R 5，R 6 R 7和R 8如本文所定义 。 还提供了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。
-
23.发明授权Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists 有权噻唑和恶唑取代的芳基酰胺作为P2X3和P2X2 / 3拮抗剂公开(公告)号：US07786110B2
公开(公告)日：2010-08-31
申请号：US11983225
申请日：2007-11-08
IPC分类号： C07D417/12 , C07D277/30 , C07D263/32 , C07D413/12 , C07D277/66 , A61K31/497 , A61K31/5355 , A61K31/428 , A61K31/426 , A61K31/421 , A61K31/541 , A61P13/00 , A61P11/00 , C07D409/14 , C07D417/10
CPC分类号： C07D401/14 , C07D263/32 , C07D277/30 , C07D277/66
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is a group of formula A or formula B, and X, R2, R3, R4, R5, R6, Ra and Rb are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R1是式A或式B的基团，X，R2，R3，R4，R5，R6，Ra和Rb如本文所定义。 还提供了使用该化合物治疗由P2X3和/或P2X2 / 3受体拮抗剂介导的疾病的方法和制备本发明化合物的方法。
-
24.发明申请公开(公告)号：US20090170874A1
公开(公告)日：2009-07-02
申请号：US12317017
申请日：2008-12-17
IPC分类号： A61K31/497 , C07D403/12 , C07D401/14 , C07D249/04 , A61K31/4192
CPC分类号： C07D403/12 , C07D249/06 , C07D401/14
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted triazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R 1为任选取代的三唑基，R 2，R 3，R 4，R 5，R 6，R 7和R 8如本文所定义。 还公开了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。
-
25.发明申请公开(公告)号：US20090163502A1
公开(公告)日：2009-06-25
申请号：US12317026
申请日：2008-12-17
IPC分类号： A61K31/5377 , A61K31/4965 , A61K31/44 , A61K31/41 , C07D413/12 , C07D401/14 , C07D401/10 , C07D257/00 , C07D405/10
CPC分类号： C07D257/04 , C07D401/10 , C07D401/14 , C07D405/12 , C07D409/14 , C07D413/12 , C07D471/04
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5, R6 R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R 1为任选取代的四唑基，R 2为任选取代的苯基，任选取代的吡啶基或任选取代的噻吩基，R 3，R 4，R 5，R 6 R 7和R 8如本文所定义 。 还提供了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。
-
26.发明申请公开(公告)号：US20150191487A1
公开(公告)日：2015-07-09
申请号：US14151680
申请日：2014-01-09
IPC分类号： C07D498/08 , C07D241/12 , C07D405/12 , C07D403/12 , C07D401/14 , C07D401/12 , C07D417/12 , C07D491/107 , C07D471/04 , C07D257/04 , C07D409/12
CPC分类号： A61K31/41 , A61K31/4439 , A61K31/497 , A61K31/5377 , C07D241/12 , C07D257/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D407/10 , C07D409/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D491/10 , C07D491/107 , C07D498/08
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R 1为任选取代的四唑基，R 2为任选取代的苯基，任选取代的吡啶基或任选取代的噻吩基，R 3，R 4，R 5和R 6如本文所定义。 还提供了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。
-
27.发明授权Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists 有权噻唑和恶唑取代的芳基酰胺作为P2X3和P2X2 / 3拮抗剂公开(公告)号：US08501933B2
公开(公告)日：2013-08-06
申请号：US12843563
申请日：2010-07-26
IPC分类号： C07D345/00 , C07D517/00
CPC分类号： A61K31/5377 , A61K31/42 , A61K31/421 , A61K31/425 , A61K31/426 , A61K31/428 , A61K31/501 , C07D261/08 , C07D263/32 , C07D275/02 , C07D277/30 , C07D277/56 , C07D277/66 , C07D413/14 , C07D417/10 , C07D417/12 , C07D417/14
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is a group of formula A or formula B, and X, R2, R3, R4, R5, R6, Ra and Rb are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R1是式A或式B的基团，X，R2，R3，R4，R5，R6，Ra和Rb如本文所定义。 还提供了使用该化合物治疗由P2X3和/或P2X2 / 3受体拮抗剂介导的疾病的方法和制备本发明化合物的方法。
-
28.发明申请公开(公告)号：US20130165443A1
公开(公告)日：2013-06-27
申请号：US13592625
申请日：2012-08-23
IPC分类号： C07D241/12 , C07D307/68 , C07C237/32 , C07D213/81 , C07D277/56 , C07D417/12 , C07D263/34 , C07D231/14 , C07D265/30 , C07D403/12 , C07D401/12 , C07D405/14 , C07D333/38 , C07D261/18
CPC分类号： C07D241/12 , C07C237/32 , C07C237/42 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D213/56 , C07D213/61 , C07D213/81 , C07D231/14 , C07D241/24 , C07D261/18 , C07D263/34 , C07D265/30 , C07D277/56 , C07D285/06 , C07D295/125 , C07D307/68 , C07D309/08 , C07D333/38 , C07D401/12 , C07D403/12 , C07D405/14 , C07D417/12
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted phenyl or optionally substituted pyridinyl, and R2, R3, R4, R5, R6, R7, R8 and R9 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R 1为任选取代的苯基或任选取代的吡啶基，R 2，R 3，R 4，R 5，R 6，R 7，R 8和R 9如本文所定义。 还公开了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。
-
公开(公告)号：US08283383B2
公开(公告)日：2012-10-09
申请号：US12820577
申请日：2010-06-22
IPC分类号： A61K31/015
CPC分类号： C07D241/12 , C07C237/32 , C07C237/42 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D213/56 , C07D213/61 , C07D213/81 , C07D231/14 , C07D241/24 , C07D261/18 , C07D263/34 , C07D265/30 , C07D277/56 , C07D285/06 , C07D295/125 , C07D307/68 , C07D309/08 , C07D333/38 , C07D401/12 , C07D403/12 , C07D405/14 , C07D417/12
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted phenyl or optionally substituted pyridinyl, and R2, R3, R4, R5, R6, R7, R8 and R9 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.
摘要翻译： 式I化合物或其药学上可接受的盐，其中R 1为任选取代的苯基或任选取代的吡啶基，R 2，R 3，R 4，R 5，R 6，R 7，R 8和R 9如本文所定义。 还公开了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。
-
30.发明申请METHODS OF USING DIAMINOPYRIMIDINE AS P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES 有权使用二氨基嘧啶作为P2X3和P2X2 / 3受体调节剂治疗呼吸道感染和胃肠疾病的方法公开(公告)号：US20120122859A1
公开(公告)日：2012-05-17
申请号：US13186078
申请日：2011-07-19
申请人： Chris Allen Broka , David Scott Carter , Michael Patrick Dillon , Anthony P.D.W. Ford , Ronald Charles Hawley , Alam Jahangir , Amy Geraldine Moore , Daniel Warren Parish
发明人： Chris Allen Broka , David Scott Carter , Michael Patrick Dillon , Anthony P.D.W. Ford , Ronald Charles Hawley , Alam Jahangir , Amy Geraldine Moore , Daniel Warren Parish
IPC分类号： A61K31/505 , A61P11/00 , A61K31/506 , A61K31/5383
CPC分类号： A61K31/506 , A61K31/505 , A61K31/513 , A61K31/538 , Y10S514/826
摘要： Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
摘要翻译： 用于治疗由P2X3和/或P2X2 / 3受体拮抗剂介导的呼吸道和胃肠道疾病的方法，所述方法包括向有需要的受试者施用有效量的式（I）化合物或其药学上可接受的盐， 其中D，X，Y，R 1，R 2，R 3，R 4，R 5，R 6，R 7和R 8如本文所定义。
-
-
-
-
-
-
-
-
-
搜索结果
44 条记录 (耗时 0.048 秒)
